Safety and efficacy of meropenem in hospitalised children: Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin

D. Schuler, E. Bodart, K. Blahova, K. Dlask, J. Hrdlicka, J. L. Andre, P. Barthe, B. Boudailliez, G. Champion, M. Foulard, J. Geisert, E. Mallet, A. Menget, J. B. Palcoux, F. Dicso, T. Hirsch, P. Tekulics, E. Colyn, J. Erasmus

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In this multicentre, randomised study of 170 children hospitalised with bacterial infections, meropenem (10 to 20 mg/kg every 8 h) was found to be as effective and as well tolerated as cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole. Most drug-related adverse events were mild and self-limiting. Neither regimen was associated with seizures. The overall incidence of clinically significant laboratory changes was similar in the two treatment groups. Satisfactory clinical responses were obtained in 94/96 (98%) patients treated with meropenem monotherapy and 43/46 (93%) children treated with cefotaxime regimens, while satisfactory bacteriological responses were obtained in 25/28 (89%) and 9/10 (90%) patients, respectively. Meropenem monotherapy appears to be a well-tolerated and effective drug for paediatric infections.

Original languageEnglish
Pages (from-to)99-108
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume36
Issue numberSUPPL. A
Publication statusPublished - 1995

Fingerprint

meropenem
Hospitalized Child
Amikacin
Cefotaxime
Metronidazole
Safety
Drug-Related Side Effects and Adverse Reactions
Bacterial Infections
Seizures
Pediatrics
Incidence
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Safety and efficacy of meropenem in hospitalised children : Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. / Schuler, D.; Bodart, E.; Blahova, K.; Dlask, K.; Hrdlicka, J.; Andre, J. L.; Barthe, P.; Boudailliez, B.; Champion, G.; Foulard, M.; Geisert, J.; Mallet, E.; Menget, A.; Palcoux, J. B.; Dicso, F.; Hirsch, T.; Tekulics, P.; Colyn, E.; Erasmus, J.

In: Journal of Antimicrobial Chemotherapy, Vol. 36, No. SUPPL. A, 1995, p. 99-108.

Research output: Contribution to journalArticle

Schuler, D, Bodart, E, Blahova, K, Dlask, K, Hrdlicka, J, Andre, JL, Barthe, P, Boudailliez, B, Champion, G, Foulard, M, Geisert, J, Mallet, E, Menget, A, Palcoux, JB, Dicso, F, Hirsch, T, Tekulics, P, Colyn, E & Erasmus, J 1995, 'Safety and efficacy of meropenem in hospitalised children: Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin', Journal of Antimicrobial Chemotherapy, vol. 36, no. SUPPL. A, pp. 99-108.
Schuler, D. ; Bodart, E. ; Blahova, K. ; Dlask, K. ; Hrdlicka, J. ; Andre, J. L. ; Barthe, P. ; Boudailliez, B. ; Champion, G. ; Foulard, M. ; Geisert, J. ; Mallet, E. ; Menget, A. ; Palcoux, J. B. ; Dicso, F. ; Hirsch, T. ; Tekulics, P. ; Colyn, E. ; Erasmus, J. / Safety and efficacy of meropenem in hospitalised children : Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. In: Journal of Antimicrobial Chemotherapy. 1995 ; Vol. 36, No. SUPPL. A. pp. 99-108.
@article{86457078b417418883db16ecc2a8ffa2,
title = "Safety and efficacy of meropenem in hospitalised children: Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin",
abstract = "In this multicentre, randomised study of 170 children hospitalised with bacterial infections, meropenem (10 to 20 mg/kg every 8 h) was found to be as effective and as well tolerated as cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole. Most drug-related adverse events were mild and self-limiting. Neither regimen was associated with seizures. The overall incidence of clinically significant laboratory changes was similar in the two treatment groups. Satisfactory clinical responses were obtained in 94/96 (98{\%}) patients treated with meropenem monotherapy and 43/46 (93{\%}) children treated with cefotaxime regimens, while satisfactory bacteriological responses were obtained in 25/28 (89{\%}) and 9/10 (90{\%}) patients, respectively. Meropenem monotherapy appears to be a well-tolerated and effective drug for paediatric infections.",
author = "D. Schuler and E. Bodart and K. Blahova and K. Dlask and J. Hrdlicka and Andre, {J. L.} and P. Barthe and B. Boudailliez and G. Champion and M. Foulard and J. Geisert and E. Mallet and A. Menget and Palcoux, {J. B.} and F. Dicso and T. Hirsch and P. Tekulics and E. Colyn and J. Erasmus",
year = "1995",
language = "English",
volume = "36",
pages = "99--108",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. A",

}

TY - JOUR

T1 - Safety and efficacy of meropenem in hospitalised children

T2 - Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin

AU - Schuler, D.

AU - Bodart, E.

AU - Blahova, K.

AU - Dlask, K.

AU - Hrdlicka, J.

AU - Andre, J. L.

AU - Barthe, P.

AU - Boudailliez, B.

AU - Champion, G.

AU - Foulard, M.

AU - Geisert, J.

AU - Mallet, E.

AU - Menget, A.

AU - Palcoux, J. B.

AU - Dicso, F.

AU - Hirsch, T.

AU - Tekulics, P.

AU - Colyn, E.

AU - Erasmus, J.

PY - 1995

Y1 - 1995

N2 - In this multicentre, randomised study of 170 children hospitalised with bacterial infections, meropenem (10 to 20 mg/kg every 8 h) was found to be as effective and as well tolerated as cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole. Most drug-related adverse events were mild and self-limiting. Neither regimen was associated with seizures. The overall incidence of clinically significant laboratory changes was similar in the two treatment groups. Satisfactory clinical responses were obtained in 94/96 (98%) patients treated with meropenem monotherapy and 43/46 (93%) children treated with cefotaxime regimens, while satisfactory bacteriological responses were obtained in 25/28 (89%) and 9/10 (90%) patients, respectively. Meropenem monotherapy appears to be a well-tolerated and effective drug for paediatric infections.

AB - In this multicentre, randomised study of 170 children hospitalised with bacterial infections, meropenem (10 to 20 mg/kg every 8 h) was found to be as effective and as well tolerated as cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole. Most drug-related adverse events were mild and self-limiting. Neither regimen was associated with seizures. The overall incidence of clinically significant laboratory changes was similar in the two treatment groups. Satisfactory clinical responses were obtained in 94/96 (98%) patients treated with meropenem monotherapy and 43/46 (93%) children treated with cefotaxime regimens, while satisfactory bacteriological responses were obtained in 25/28 (89%) and 9/10 (90%) patients, respectively. Meropenem monotherapy appears to be a well-tolerated and effective drug for paediatric infections.

UR - http://www.scopus.com/inward/record.url?scp=0029068720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029068720&partnerID=8YFLogxK

M3 - Article

C2 - 8543503

AN - SCOPUS:0029068720

VL - 36

SP - 99

EP - 108

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. A

ER -